The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 18 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 1 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Canaris: CurieDx Proof-of-Concept UTI Model Achieves 88% Accuracy
“And we have, just on the proof of concept model, we have 88% accuracy on that.”
CurieDx's strep diagnostic is 88% accurate, beating physician visual evaluations
“The rapid swab that you traditionally do at the doctor's office, the one that comes back in 15 minutes, that's about 95% accurate, so it's good, but it's not perfect, and, ah, the, you know, physicians are 64%, so we are around 88% right now accuracy”
Middleton projects CurieDx will make $500K annually, rejecting founder's $6M estimate
“The financial part, she needs to button up, because my math is she'll make 500,000 dollars a year in the next two years, not six million.”
Dr. Canaris: CurieDx could raise $2M for sales and fund R&D via grants
“So, since Josh asked, yeah, if we were to do something on the order of two million, would that sound more like in range? And then what we would accomplish there is just sales, and we leave R&D stuff for federal grant funding.”
CurieDx will pivot from direct-to-consumer back to B2B in Q3 2025
“The intention is direct to consumer for the relatively short period, around six months from now, so like Q three of 25, we start pouring efforts back into the B to B component and slowly build up that urgent care and small to medium practice customer base.”
CurieDX is raising $4M to reach 10,000 patients and secure FDA clearance
“We're now raising four million, which helps us reach our first 10,000 patients and get the strep product through FDA from a screening tool to a diagnostic.”
Advisors say enterprise health organizations evaluate strategic partnerships at 10,000 users
“We have advisors at Amazon One Medical and also Care First Blue Cross Blue Shield and feedback that they've given us is when we get into the 10,000 user range, that's when they start paying attention and looking at strategic partnerships.”
Jesse Middleton passes on Curie DX's current raise structure
“And so I just think that if it changed, we may be interested, but in the current raise, it's probably not a fit for us.”
CurieDx charges small practices $10,000 annually for 500 patient uses
“So we are starting as a B to B SaaS, so subscription model, where small to medium practice, either whether it's primary care or urgent care, 10,000 dollars a year, that would get about 500 uses.”
CurieDX has partnered with eight physician practices covering 40 states
“Just in the last three weeks, we've partnered with eight physician practices covering 40 states to pair telehealth with our app.”
Paige Finn Doherty passes on Curie DX's multi-variable $4M raise
“If that's something that you are open to considering, I think we should continue the conversation, but the four million dollar raise with many variables is less of a fit for us.”
CurieDX has raised over $1.5M in capital and submitted two patents
“We've submitted two patent applications and received over 1.5 million in non-dilutive and investment capital.”
Elizabeth Yin passes on Curie DX over parallel execution strategy
“I think echoing all these points, it's like too much, all in parallel in one race, so I'm out.”
Charles Hudson passes on investing in Curie DX
“So I'm not in now, given the current state of the product and the tech.”
CurieDx Plans Clinical Trials for FDA Diagnostic Approval in Q4 2025
“The intention is to go through clinical trials, which we're planning for in Q four of 25, go through FDA and get approved as a diagnostic.”
Jenny Fielding passes on Curie DX over multi-model approach and FDA complexity
“I think with multiple business models, a four million dollar raise, which is, you know, quite high for me as a pre-seed, and the FDA path, I think that's going to be just a complicated one for me to get my head around, so I think I'm out.”